Sabine Mueller

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid...

Tolerability is defined as the proportion of participants receiving at least one dose of combination gemcitabine and paxalisib with a reported dose-limiting toxicity (DLT) during cycle 1 for all participants in Phase I.

Recruiting

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

Proportion of participants in Phase 1 with treatment-emergent adverse events as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0) will be reported.

Recruiting

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

The Rebound rate is defined as increase in tumor size by 25% or more by Response Assessment in Pediatric Neuro-Oncology-Low Grade Glioma (RAPNO-LGG) criteria and/or clinical progression necessitating the re-institution of therapy ...

Recruiting

Embryonal Tumor With Multilayered Rosettes

The median PFS6 is defined as the median number of months for participants in Cohort 1 who have remained progression-free from the date of initial surgical resection until 6 months.

Recruiting

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residu...

Proportion of participants with adverse events of L-T3 as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0)

Recruiting

Efficacy of Laser Interstitial Thermal Therapy in Young Persons With Low-grade Glioma

PFS is defined as proportion of participants who do not experience further disease progression at 15 months following and assessed by MRI according to Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria.

Recruiting

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Epen...

Proportion of participants with a 10% reduction in Enhancer of Zeste Inhibitory Protein (EZHIP) and/or a 10% increase in the epigenetic modification to the DNA packaging protein histone H3, with tri-methylation of lysine 27 on his...

Recruiting

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Percentage of participants alive and free from progression at 6 months after the diagnosis. The primary analysis for PFS6 is based on the intention to treat (ITT) population, according to treatment arm assignment. PFS6 is estimate...

Recruiting

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Gli...

Will assess the percentage change in cell cycle-related genetic signature post administration of neoadjuvant treatments when compared to archived recurrent pediatric HGG group. The number of participants with high cell cycle gene ...

Recruiting

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Progression-free survival is defined as the time of documented response until disease progression as defined by Response assessment in neuro-oncology criteria (RANO) criteria. PFS will be reported by overall group at 12 months.

Recruiting